復星醫藥(02196.HK)以450萬人幣收購大健康數字化應用平台開發商
復星醫藥(02196.HK)公布,附屬公司復星醫藥產業,與控股股東復星高科技的附屬公司復星健控訂立股權轉讓協議。據此,復星醫藥產業同意向其購買易研雲(上海)醫療科技有限公司(目標公司)全部股權,以450萬元人民幣現金為交易代價。於股權轉讓協議項下交易完成後,目標公司將成為公司之全資附屬公司。
公司指,目標公司主要從事大健康領域數字化應用平台的開發。是次交易旨在強化集團藥品研發項目管理的數字化能力,進一步完善藥品研發體系、提升管理效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.